YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx, Inc. ARDX is a biopharmaceutical company developing medicines for unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been…
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic's Claude AI recently…
JEFFERSONVILLE, Ind. and MORRISVILLE, N.C., Aug. 18, 2026 /PRNewswire/ -- Valeris, an integrated commercialization partner helping life sciences companies connect market access, patient services, and commercial strategy, today announced th…
[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) is down ~13% in Friday morning trading after lowering [https://seekingalpha.com/news/4628428-ardelyx-gaap-eps-of-0_0…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx, Inc. ARDX develops and commercializes therapies for gastrointestinal and kidney diseases. The Zacks Consensus Estimate for its current year earnings has be…
Key Points Interested in Ardelyx, Inc.? Here are five stocks we like better. Second-quarter product revenue reached a record $118 million, up 31% year over year, but Ardelyx lowered its 2026 IBSRELA revenue forecast to $350 million–$370 mi…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx ARDX is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised almost 14.3% downward over t…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Arbor Realty Trust, Inc. ABR is a real estate investment trust. The Zacks Consensus Estimate for its current year earnings has been revised 13% downward over the la…
Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patie…
[Judge gavel on the table with blurry books in the background] greenleaf123 Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) shares fell ~6% on Friday after the company lost an appeal against the Health and Human Services Department r…
Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is cur…
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Ardelyx Inc. (NASDAQ:ARDX) ranks #9 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 30 Biotech comp…
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs,…
Earnings Call Insights: Ardelyx (ARDX) Q1 2026 MANAGEMENT VIEW * “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding that…
Ardelyx, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Positioning Ibsrela revenue grew 58% year-over-year, driven by disciplined commercial execution and a strategy focused on positioning the drug as the first-l…
Image source: The Motley Fool. DATE Apr. 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Michael Raab Chief Commercial Officer — Eric Foster Chief Financial Officer — Sue Hohenleitner Need a quote from a Motley Fool an…
Major earnings expected after the bell on Thursday include: * Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) * Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) * Roku (ROKU [https://seekingalpha.com/symbol/ROKU]) * Twilio (TWLO [ht…
Ardelyx, Inc. WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs,…
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet s…
Key Points Michael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026. The transaction represented 2.21% of Michael Raab's aggregate and…
Michael Raab, President & CEO of Ardelyx(NASDAQ:ARDX), reported a sale of 41,666 shares of Common Stock for a transaction value of approximately $243,000 on March 16, 2026, according to a SEC Form 4 filing. Transaction summary Metric Value…
Key Points Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time of the transaction. Raab reta…
On Feb. 24, 2026, Ardelyx(NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 41…
Ardelyx, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Positioning IBSRELA achieved 73% revenue growth in 2025, driven by a first-in-class mechanism that addresses the 77% of IBS-C patients who remain symptomat…
We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. Ardelyx, Inc. (NASDAQ:ARDX) reported preliminary, unaudited product revenue results for the fourth quarter and full year 2025, along with expected product…
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medi…
Ardelyx (ARDX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formu…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list. TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.…
Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target from $8 to $15. Earlier, on January 9, Ju…
VANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding…
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Ardelyx (ARDX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to…
Ardelyx (ARDX) shares ended the last trading session 5.5% higher at $6.15. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.5% loss over the pas…
[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] * Shares of Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) added ~8% on Friday after Bloomberg quoted a Raymond James analyst reporting that the company has…
Image source: The Motley Fool. DATE Oct. 30, 2025 CALL PARTICIPANTS President and Chief Executive Officer — Michael Raab Chief Commercial Officer — Eric Foster Chief Financial and Operations Officer — Justin Renz Head of Investor Relations…
Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earli…